123 related articles for article (PubMed ID: 16493252)
1. Consolidation therapy in ovarian cancer: where do we stand?
Dearnley DD; McMeekin DS
Curr Opin Obstet Gynecol; 2006 Feb; 18(1):3-7. PubMed ID: 16493252
[TBL] [Abstract][Full Text] [Related]
2. Novel therapies for recurrent ovarian cancer management.
Bhoola SM; Alvarez RD
Expert Rev Anticancer Ther; 2004 Jun; 4(3):437-48. PubMed ID: 15161442
[TBL] [Abstract][Full Text] [Related]
3. The role of maintenance chemotherapy in advanced nonsmall cell lung cancer.
Jalal SI; Ademuyiwa FO; Hanna NH
Curr Opin Oncol; 2009 Mar; 21(2):110-5. PubMed ID: 19532011
[TBL] [Abstract][Full Text] [Related]
4. Duration of chemotherapy with topotecan influences survival in recurrent ovarian cancer: a meta-analysis.
Möbus V; Kieback DG; Kaubitzsch SK
Anticancer Res; 2007; 27(3B):1581-7. PubMed ID: 17595779
[TBL] [Abstract][Full Text] [Related]
5. Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments.
Kyrgiou M; Salanti G; Pavlidis N; Paraskevaidis E; Ioannidis JP
J Natl Cancer Inst; 2006 Nov; 98(22):1655-63. PubMed ID: 17105988
[TBL] [Abstract][Full Text] [Related]
6. [Intraperitoneal chemotherapy for ovarian cancer].
Noma J; Yoshida N
Gan To Kagaku Ryoho; 2008 Jun; 35(6):885-90. PubMed ID: 18633214
[TBL] [Abstract][Full Text] [Related]
7. Cytoreductive surgery and perioperative intraperitoneal chemotherapy for the treatment of advanced primary and recurrent ovarian cancer.
Sugarbaker PH
Curr Opin Obstet Gynecol; 2009 Feb; 21(1):15-24. PubMed ID: 19124999
[TBL] [Abstract][Full Text] [Related]
8. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy.
Juretzka MM; Barakat RR; Chi DS; Iasonos A; Dupont J; Abu-Rustum NR; Poynor EA; Aghajanian C; Spriggs D; Hensley ML; Sabbatini P
Gynecol Oncol; 2007 Jan; 104(1):176-80. PubMed ID: 16996584
[TBL] [Abstract][Full Text] [Related]
9. Advanced ovarian cancer: a clinical update on first-line treatment, recurrent disease, and new agents.
Ozols RF
J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S60-73. PubMed ID: 19780247
[TBL] [Abstract][Full Text] [Related]
10. Maintenance or consolidation therapy in advanced ovarian cancer.
Pectasides D; Pectasides E
Oncology; 2006; 70(5):315-24. PubMed ID: 17164587
[TBL] [Abstract][Full Text] [Related]
11. Pros and cons for systemic therapy in recurrent ovarian cancer.
Oskay-Ozcelik G; Sehouli J
Anticancer Res; 2009 Jul; 29(7):2831-6. PubMed ID: 19596970
[TBL] [Abstract][Full Text] [Related]
12. Cytoreductive surgery for recurrent ovarian cancer.
Hauspy J; Covens A
Curr Opin Obstet Gynecol; 2007 Feb; 19(1):15-21. PubMed ID: 17218846
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant chemotherapy for early-stage ovarian cancer: review of the literature.
Tropé C; Kaern J
J Clin Oncol; 2007 Jul; 25(20):2909-20. PubMed ID: 17617522
[TBL] [Abstract][Full Text] [Related]
14. Intraperitoneal chemotherapy for ovarian cancer.
Hamilton CA; Berek JS
Curr Opin Oncol; 2006 Sep; 18(5):507-15. PubMed ID: 16894301
[TBL] [Abstract][Full Text] [Related]
15. Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).
Meier W; du Bois A; Reuss A; Kuhn W; Olbricht S; Gropp M; Richter B; Lück HJ; Kimmig R; Pfisterer J
Gynecol Oncol; 2009 Aug; 114(2):199-205. PubMed ID: 19446314
[TBL] [Abstract][Full Text] [Related]
16. Management of recurrent ovarian carcinoma: current status and future directions.
Martin LP; Schilder RJ
Semin Oncol; 2009 Apr; 36(2):112-25. PubMed ID: 19332246
[TBL] [Abstract][Full Text] [Related]
17. Pegylated liposomal doxorubicin consolidation therapy after platinum/paclitaxel-based chemotherapy for suboptimally debulked, advanced-stage epithelial ovarian cancer patients.
Rocconi RP; Straughn JM; Leath CA; Kilgore LC; Huh WK; Barnes MN; Partridge EE; Alvarez RD
Oncologist; 2006 Apr; 11(4):336-41. PubMed ID: 16614229
[TBL] [Abstract][Full Text] [Related]
18. Intraperitoneal chemotherapy in ovarian cancer: an update.
Runowicz CD
Cancer J; 2008; 14(1):7-9. PubMed ID: 18303475
[TBL] [Abstract][Full Text] [Related]
19. Ovarian cancer: a focus on management of recurrent disease.
Herzog TJ; Pothuri B
Nat Clin Pract Oncol; 2006 Nov; 3(11):604-11. PubMed ID: 17080178
[TBL] [Abstract][Full Text] [Related]
20. Sequential, alternating, and maintenance/consolidation chemotherapy in advanced non-small cell lung cancer: a review of the literature.
Grossi F; Aita M; Follador A; Defferrari C; Brianti A; Sinaccio G; Belvedere O
Oncologist; 2007 Apr; 12(4):451-64. PubMed ID: 17470688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
